Cargando…

Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy

The relationship between hyperuricemia, gout, and renal disease has been investigated for several years. From the beginning, kidney disease has been considered a complication of gout; however, the viewpoints changed, claiming that hypertension and elevated uric acid (UA) levels are caused by decreas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Tao Han, Chen, Jia-Jin, Wu, Chao-Yi, Yang, Chih-Wei, Yang, Huang-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466342/ https://www.ncbi.nlm.nih.gov/pubmed/34574015 http://dx.doi.org/10.3390/diagnostics11091674

Ejemplares similares

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

Urate-Lowering Therapy Ameliorates Kidney Function in Type 2 Diabetes Patients With Hyperuricemia
por: Ueno, Naohiko
Publicado: (2017)

Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis
por: Sharma, Gaurav, et al.
Publicado: (2021)

Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis
por: Zhang, Lin, et al.
Publicado: (2022)

Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 – 4 chronic kidney disease: Controversial role of kidney function
por: Jeon, Hee Jung, et al.
Publicado: (2019)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
por: Chen, Mo, et al.
Publicado: (2020)

An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia
por: Bove, Marilisa, et al.
Publicado: (2017)

Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy
por: Chiu, Yi-Chih, et al.
Publicado: (2021)

Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis
por: Li, Shu, et al.
Publicado: (2016)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2013)

Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis
por: Zhu, Junyu, et al.
Publicado: (2020)

Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis
por: Zhao, Li, et al.
Publicado: (2020)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
por: Kataoka, Hiroshi, et al.
Publicado: (2022)

Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients
por: Chung, Ting-Ting, et al.
Publicado: (2019)

The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality
por: Gonzalez-Martin, Guillermo, et al.
Publicado: (2020)

ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload
por: Matsuo, Hirotaka, et al.
Publicado: (2014)

Urate‐induced immune programming: Consequences for gouty arthritis and hyperuricemia
por: Cabău, Georgiana, et al.
Publicado: (2019)

The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia
por: Wu, Liting, et al.
Publicado: (2021)

Common UCP2 variants contribute to serum urate concentrations and the risk of hyperuricemia
por: Yang, Luyu, et al.
Publicado: (2016)

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis
por: Kanji, Tahir, et al.
Publicado: (2015)

Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease
por: Mitri, Ghaith, et al.
Publicado: (2016)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
por: Hoque, Kazi Mirajul, et al.
Publicado: (2020)

Vegan Diet Is Associated with a Lower Risk of Chronic Kidney Disease in Patients with Hyperuricemia
por: Wu, Chia-Lin, et al.
Publicado: (2023)

Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease
por: Waheed, Yousuf, et al.
Publicado: (2021)

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
por: Janssen, C. A., et al.
Publicado: (2018)

Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
por: Honda, Masataka, et al.
Publicado: (2021)

Decreased extra-renal urate excretion is a common cause of hyperuricemia
por: Ichida, Kimiyoshi, et al.
Publicado: (2012)

Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
por: Sapankaew, Tunlanut, et al.
Publicado: (2022)

Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency
por: Wu, Mian, et al.
Publicado: (2021)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

Quantitative Estimation of Urate Transport in Nephrons in Relation to Urinary Excretion Employing Benzbromarone-Loading Urate Clearance Tests in Cases of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2011)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Catalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in Hominoids
por: Marchetti, Marialaura, et al.
Publicado: (2016)

Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2
por: Matsuo, Hirotaka, et al.
Publicado: (2016)

Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
por: Liang, Xiuping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_64lm1276avs3sbji54haoqm2uh